Two hundred and sixty-one women of fertile age were treated with Restovar, a new oral contraceptive containing 0·75 mg lynestrenol and 0·0375 mg ethinyloestradiol per tablet. During the observation period, totalling 2,544 cycles, no pregnancies occurred. The acceptability was excellent in 97% of the women and side-effects were rare and then only mild.
Get full access to this article
View all access options for this article.
References
1.
Aznar-RamosRGiner-VelázquezJLara-RicaldeRMartinez-ManautouJ (1969) Incidence of side-effects with contraceptive placebo. American Journal Obstetrics and Gynecology105, 1144
2.
GoldzieherJWMosesLEAverkinEScheelCTaberBZ (1971) A placebo-controlled double-blind crossover investigation of the side-effects attributed to oral contraceptives. Fertility and Sterility22, 609
3.
HellmanLSartwellPE (1969) Second Report on Oral Contraceptives. Advisory Committee on Obstetrics and Gynecology, Food and Drug Administration, Washington DC
4.
InmanWHWVesseyMP (1968) Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. British Medical Journal2, 193
5.
Royal College of General Practitioners (1967) Oral contraception and thrombo-embolic disease. Journal of the College of General Practitioners13, 267
VesseyMPDollR (1968) Investigation of relation between use of oral contraceptives and thromboembolic disease. British Medical Journal2, 199
8.
VesseyMPDollR (1969) Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. British Medical Journal2, 651
